(Entertainment Industry Foundation) A new, innovative approach to lung cancer treatment, administration of immunotherapy prior to surgery yielded encouraging outcomes in findings from SU2C-CRI Dream Team researchers. Two doses of anti-PD1 immunotherapy nivolumab several weeks prior to surgery was found to be safe; 45 percent of the trial patients showed little evidence of disease upon follow-up; and patients' immune systems intercepted circulating tumor cells to potentially prevent recurrence and metastasis, consistent with SU2C's research focus on Cancer Interception.
from EurekAlert! - Social and Behavioral Science https://ift.tt/2H3VPl6
No comments:
Post a Comment